Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting | ||
By: PR Newswire Association LLC. - 23 Nov 2022 | Back to overview list |
|
Presentation to highlight data from the ongoing long-term open-label extension study of leniolisib, a PI3K? inhibitor under investigation for APDS, a rare primary immunodeficiency LEIDEN, Netherlands, Nov. 23, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces today that new clinical data for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3K?) inhibitor, an investigational treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, will be presented by V. Koneti Rao, MD, FRCPA, staff physician in the Primary Immune Deficiency Clinic at the National Institute of Health in Bethesda, Maryland, at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, in New Orleans, Louisiana taking place from Saturday, December 10 through Tuesday, December 13, 2022. Information regarding Pharming's data presentation can be found below, and on the ASH conference website: https://www.hematology.org/meetings/annual-meeting. Presentation title: Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3K? Inhibitor Leniolisib for Patients with Activated PI3K? Delta Syndrome (APDS) through December 2021 Presentation type: oral Session name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Delineating Immunity from Mice to Humans Abstract number: 608 Session date and time: Monday, December 12, 2022 from 10:30AM – 12:30PM CST Presentation date and time: Monday, December 12, 2022 at 10:45AM CST Location: Room: Ernest N. Morial Convention Center, 278-282 About Activated Phosphoinositide 3-Kinase ? Syndrome (APDS) About Leniolisib About Pharming Group N.V. For more information, visit www.pharming.com. Forward-Looking Statements This press release contains forward-looking statements, including with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, Pharming's ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. References 1. Lucas CL, et al. Nat Immunol. 2014; 15:88-97. Logo: https://mma.prnewswire.com/media/1778344/Pharming_Group_NV_Logo.jpg View original content:https://www.prnewswire.co.uk/news-releases/pharming-group-announces-presentation-of-new-leniolisib-data-at-2022-ash-annual-meeting-301685691.html |
||
|
||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |